Rapid communication Open Access
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.3.1800698
Like 0
Access full text
Article
- Emi Takashita1, Chiharu Kawakami2, Hiroko Morita1, Rie Ogawa1, Seiichiro Fujisaki1, Masayuki Shirakura1, Hideka Miura1, Kazuya Nakamura1, Noriko Kishida1, Tomoko Kuwahara1, Keiko Mitamura3, Takashi Abe4, Masataka Ichikawa5, Masahiko Yamazaki6, Shinji Watanabe1, Takato Odagiri1, on behalf of the Influenza Virus Surveillance Group of Japan7
-
View Affiliations Hide AffiliationsAffiliations: 1 Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan 2 Yokohama City Institute of Public Health, Kanagawa, Japan 3 Eiju General Hospital, Tokyo, Japan 4 Abe Children’s Clinic, Kanagawa, Japan 5 Ichikawa Children’s Clinic, Kanagawa, Japan 6 Zama Children’s Clinic, Kanagawa, Japan 7 The members of the group are listed at the end of the articleCorrespondence:Takato Odagiritodagiri nih.go.jp
-
View Citation Hide Citation
Citation style for this article: Takashita Emi, Kawakami Chiharu, Morita Hiroko, Ogawa Rie, Fujisaki Seiichiro, Shirakura Masayuki, Miura Hideka, Nakamura Kazuya, Kishida Noriko, Kuwahara Tomoko, Mitamura Keiko, Abe Takashi, Ichikawa Masataka, Yamazaki Masahiko, Watanabe Shinji, Odagiri Takato, on behalf of the Influenza Virus Surveillance Group of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3):pii=1800698. https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698 Received: 21 Dec 2018; Accepted: 16 Jan 2019
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
Abstract
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.
Article metrics loading...
/content/10.2807/1560-7917.ES.2019.24.3.1800698
2019-01-17
2020-01-28
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.3.1800698
-
From This Site
/content/10.2807/1560-7917.ES.2019.24.3.1800698dcterms_title,dcterms_subject,pub_keyword105 -
PubMed
-
Google Scholar
Full text loading...
/deliver/fulltext/eurosurveillance/24/3/eurosurv-24-3-4.html?itemId=/content/10.2807/1560-7917.ES.2019.24.3.1800698&mimeType=html&fmt=ahah
References
-
Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240-6. https://doi.org/10.1111/irv.12446 PMID: 28146320
-
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-23. https://doi.org/10.1056/NEJMoa1716197 PMID: 30184455
-
Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. https://doi.org/10.1038/s41598-018-27890-4 PMID: 29941893
-
Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Front Microbiol. 2018;9(3026):3026. https://doi.org/10.3389/fmicb.2018.03026 PMID: 30574137
-
Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12(4 Pt B):603-16. PMID: 17944268
-
Influenza Research Database (IRD). Analyze Sequence Variation (SNP). Bethesda: National Institute of Allergy and Infectious Diseases. [Accessed: 15 Jan 2019]. Available from: https://www.fludb.org
-
National Institute of Infectious Diseases (NID). Antiviral resistance surveillance in Japan. Tokyo: NID. [Accessed: 15 Jan 2019]. Available from: http://www.nih.go.jp/niid/en/influ-resist-e.html
-
World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87(39):369-74. PMID: 23061103
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
<p class="citation">
<span>Citation style for this article:</span>
<span class="meta-value authors">
<a href="/search?value1=Emi+Takashita&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Takashita Emi</a>,
<a href="/search?value1=Chiharu+Kawakami&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kawakami Chiharu</a>,
<a href="/search?value1=Hiroko+Morita&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Morita Hiroko</a>,
<a href="/search?value1=Rie+Ogawa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ogawa Rie</a>,
<a href="/search?value1=Seiichiro+Fujisaki&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fujisaki Seiichiro</a>,
<a href="/search?value1=Masayuki+Shirakura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Shirakura Masayuki</a>,
<a href="/search?value1=Hideka+Miura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Miura Hideka</a>,
<a href="/search?value1=Kazuya+Nakamura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nakamura Kazuya</a>,
<a href="/search?value1=Noriko+Kishida&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kishida Noriko</a>,
<a href="/search?value1=Tomoko+Kuwahara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kuwahara Tomoko</a>,
<a href="/search?value1=Keiko+Mitamura&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mitamura Keiko</a>,
<a href="/search?value1=Takashi+Abe&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Abe Takashi</a>,
<a href="/search?value1=Masataka+Ichikawa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ichikawa Masataka</a>,
<a href="/search?value1=Masahiko+Yamazaki&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Yamazaki Masahiko</a>,
<a href="/search?value1=Shinji+Watanabe&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Watanabe Shinji</a>,
<a href="/search?value1=Takato+Odagiri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Odagiri Takato</a>,
<a href="/search?value1=on+behalf+of+the+Influenza+Virus+Surveillance+Group+of+Japan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Influenza Virus Surveillance Group of Japan</a></span>.
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
<a href="/content/ecdc">Euro Surveill.</a> 2019;24(3):pii=1800698.
<a href="https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698</a>
<span class="ES_Article_citation">
<span class="generated">Received</span>: 21 Dec 2018;
<span class="generated">Accepted</span>: 16 Jan 2019
</span>
</p>
/content/10.2807/1560-7917.ES.2019.24.3.1800698
/content/10.2807/1560-7917.ES.2019.24.3.1800698
Data & Media loading...
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed